Search - Université de Rennes Access content directly

Filter your results

11 Results
Structure: Internal structure identifier : 335357

TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.

Fabrice Journe , Hichame Id Boufker , Leon van Kempen , Marie-Dominique Galibert , Murielle Wiedig et al.
British Journal of Cancer, 2011, 105 (11), pp.1726-32. ⟨10.1038/bjc.2011.451⟩
Journal articles inserm-00638967v1
Image document

A non-coding function of TYRP1 mRNA promotes melanoma growth

David Gilot , Mélodie Migault , Laura Bachelot , Fabrice Journé , Aljosja Rogiers et al.
Nature Cell Biology, 2017, 19 (11), pp.1348-1357. ⟨10.1038/ncb3623⟩
Journal articles hal-01647130v1
Image document

Head-and-Neck MRI-only radiotherapy treatment planning From acquisition in treatment position to pseudo-CT generation

A Largent , L Marage , I Gicquiau , J-C Nunes , N Reynaert et al.
Cancer/Radiothérapie, 2020, 24 (4), pp.288-297. ⟨10.1016/j.canrad.2020.01.008⟩
Journal articles hal-02532848v1
Image document

SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma

P. El Hajj , D. Gilot , M. Migault , A. Theunis , L. C. Van Kempen et al.
British Journal of Cancer, 2015, 113 (1), pp.91--98. ⟨10.1038/bjc.2015.194⟩
Journal articles hal-01175527v1

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition

Sabine Paternot , Eric Raspé , C Meiller , Maxime Tarabichi , Jean-Baptiste Assié et al.
Molecular Oncology, 2022, ⟨10.1002/1878-0261.13351⟩
Journal articles hal-03898858v1

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma

G. Manson , P. Brice , C Herbaux , A.M. Gonçalves da Silva , K Bouabdallah et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 (4), pp.1144-1153. ⟨10.1007/s00259-020-05015-2⟩
Journal articles hal-02931653v1

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Reid Merryman , Luca Castagna , Laura Giordano , Vincent Ho , Paolo Corradini et al.
Leukemia, 2021, 35 (9), pp.2672-2683. ⟨10.1038/s41375-021-01193-6⟩
Journal articles hal-03229516v1
Image document

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Emmanuel Bachy , Roch Houot , Pierre Feugier , Krimo Bouabdallah , Reda Bouabdallah et al.
Blood, 2022, 139 (15), pp.2338-2346. ⟨10.1182/blood.2021013526⟩
Journal articles hal-03679319v1

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients

P. El Hajj , F. Journe , M. Wiedig , I. Laios , F. Sales et al.
British Journal of Cancer, 2013, 108 (8), pp.1641-1647. ⟨10.1038/bjc.2013.115⟩
Journal articles hal-01064483v1
Image document

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

Aviv Ladanie , Andreas M Schmitt , Benjamin Speich , Florian Naudet , Arnav Agarwal et al.
JAMA Network Open, 2020, 3 (11), pp.e2024406. ⟨10.1001/jamanetworkopen.2020.24406⟩
Journal articles hal-03037506v1

Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma

G. Manson , P. Brice , C Herbaux , A.M. Gonçalves da Silva , K Bouabdallah et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 (5), pp.1699-1700. ⟨10.1007/s00259-021-05321-3⟩
Journal articles hal-03225167v1